

# EXHIBIT A

**Exhibit A – Joint Claim Construction Chart**

	<b>Term</b>	<b>OMAB's Construction</b>	<b>Amgen's Construction</b>	<b>Court's Construction</b>
1.	<p>“being treated with a humanized sclerostin-recognizing antibody” (’373 patent, claims 1, 3, 9, 11, 15, 24)</p> <p>“being treated with a sclerostin-recognizing antibody” (’681 patent, claims 1, 24, 29)</p> <p>“being treated with a humanized sclerostin-recognizing antibody and vitamin D” (’681 patent, claim 27)</p>	<p>Plain and ordinary meaning of the term, i.e., “at the time the method is beginning, having been undergoing treatment with a humanized sclerostin-recognizing antibody”</p> <p>Plain and ordinary meaning of the term, i.e., “at the time the method is beginning, having been undergoing treatment with a sclerostin-recognizing antibody”</p> <p>Plain and ordinary meaning of the term, i.e., “at the time the method is beginning, having been undergoing treatment with a humanized sclerostin-recognizing antibody and vitamin D.”</p>	<p>Plain and ordinary meaning of the term, i.e., “during the course of a humanized sclerostin-recognizing antibody treatment”</p> <p>Plain and ordinary meaning of the term, i.e., “during the course of a sclerostin-recognizing antibody treatment”</p> <p>Plain and ordinary meaning of the term, i.e., “during the course of treatment with both a humanized sclerostin-recognizing antibody and vitamin D.”</p>	
2.	<p>“administered... sequentially with” (’196 patent, claim 1)</p>	<p>Plain and ordinary meaning of the term, i.e., “administered such that administration of one drug follows completion of the course of treatment with the other drug”</p>	Indefinite.	

	<b>Term</b>	<b>OMAB's Construction</b>	<b>Amgen's Construction</b>	<b>Court's Construction</b>
3.	<p>“serially administered” (’373 patent, claim 14; ’681 patent, claim 12)</p> <p>“serially administering” (’373 patent, claim 15; ’681 patent, claim 29)</p> <p>“administered serially” (’681 patent, claim 28)</p>	<p>Plain and ordinary meaning of the term, i.e., “administered such that administration of the antiresorptive drug follows completion of the course of treatment with the sclerostin-recognizing antibody”</p> <p>Plain and ordinary meaning of the term, i.e., “administering such that administration of the antiresorptive drug follows completion of the course of treatment with the sclerostin-recognizing antibody”</p> <p>Plain and ordinary meaning of the term, i.e., “administered such that administration of the alendronate follows completion of the course of treatment with the sclerostin-recognizing antibody”</p>	Indefinite.	

**Agreed Constructions**

<b><u>Term</u></b>	<b><u>Agreed Construction</u></b>
“A method for promoting bone growth in a human subject being treated with a humanized sclerostin-recognizing antibody,” (’373 patent, claim 1)	The preamble is limiting, i.e., the method must be performed with the intent to promote bone growth and the method is performed in a human subject being treated with a humanized sclerostin-recognizing antibody.
“A method for increasing bone density in a human subject with low bone mass being treated with a sclerostin-recognizing antibody,” (’373 patent, claim 15)	The preamble is limiting, i.e., the method must be performed with the intent to increase bone density and the method is performed in a human subject with low bone mass being treated with a sclerostin-recognizing antibody.
“method for increasing bone formation in a human subject being treated with a sclerostin-recognizing antibody,” (’681 patent, claim 1)	The preamble is limiting, i.e., the method must be performed with the intent to increase bone formation and the method is performed in a human subject being treated with a sclerostin-recognizing antibody.
“An improved method of treating a human subject being treated with a sclerostin-recognizing antibody to increase bone formation in the human subject,” (’681 patent, claim 24)	The claim is in Jepson format.  The preamble is limiting, i.e., the method must be performed with the intent to increase bone formation and the method must be performed in a human subject being treated with a sclerostin-recognizing antibody.

<b><u>Term</u></b>	<b><u>Agreed Construction</u></b>
“A method for increasing bone formation in a human subject with low bone mineral density being treated with a humanized sclerostin-recognizing antibody and vitamin D,” (’681 Patent, claim 27)	The preamble is limiting, i.e., the method must be performed with the intent to increase bone formation and the method must be performed in a human subject with low bone mineral density being treated with a humanized sclerostin-recognizing antibody and vitamin D.
“A method for increasing bone mineral density in a human subject with low bone mass being treated with a sclerostin-recognizing antibody,” (’681 Patent, Claim 29)	The preamble is limiting, i.e., the method must be performed with the intent to increase bone mineral density and the method must be performed in a human subject with low bone mass being treated with a sclerostin-recognizing antibody.
“effective amount” (’099 patent, claim 12; ’196 patent, claim 1)	“An amount that achieves the claimed result of systemically increasing bone density.”
“administering . . . a therapeutic comprising . . . a Sclerostin antagonist . . . with an antiresorptive . . . thereby systemically increasing bone density” (’099 patent, claim 12)	“the combined effects of administering a Sclerostin antagonist and administering an antiresorptive results in systemically increasing bone density”
“administering . . . a composition comprising . . . a Sclerostin antagonist . . . with an antiresorptive drug . . . thereby systemically increasing bone density”	“the combined effects of administering a Sclerostin antagonist and administering an antiresorptive drug results in systemically increasing bone density”

<b><u>Term</u></b>	<b><u>Agreed Construction</u></b>
('196 patent, claim 1)	
“administering... a Sclerostin antagonist together with an antiresorptive drug”  ('099 patent, claim 12)	“administering the antiresorptive drug during the course of treatment with the sclerostin antagonist.”
“administration of a first antiresorptive drug . . . ; and . . . administration of a second antiresorptive drug after the administration of the first antiresorptive drug”  ('681 patent, claim 24)	“Administering to that patient a first antiresorptive drug and administering a different antiresorptive drug after the administration of the first antiresorptive drug has concluded.”